BioWorld

April 26, 2010

Come See Us at BIO 2010 And Get Your Chicago Hat

NewCo News: Catherex' Oncolytic Virus Drugs Targeting Brain, Liver Cancers

Acura Shares Plummet After FDA Panel Rejects Pain Drug Acurox

WASHINGTON - Shares of Acura Pharmaceuticals Inc. fell 32 percent Friday after an FDA advisory panel a day earlier refused to back approval of the firm's investigational pain drug Acurox (oxycodone HCl and niacin). (BioWorld Today) Read More

Pfizer's Sutent Can't Beat Onyx's Nexavar in Liver Cancer Phase III

Other News To Note

Bench Press

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...

BioWorld

April 26, 2010

Come See Us at BIO 2010 And Get Your Chicago Hat

NewCo News: Catherex' Oncolytic Virus Drugs Targeting Brain, Liver Cancers

Clinic Roundup

Stock Movers

Vital Signs

Acura Shares Plummet After FDA Panel Rejects Pain Drug Acurox

Pfizer's Sutent Can't Beat Onyx's Nexavar in Liver Cancer Phase III

Other News To Note

Bench Press

Today's news in brief

Today's news in brief

Epigenetic technology could eliminate misfolded prion proteins

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

Brenig Therapeutics discovers new LRRK2 inhibitors